Core Viewpoint - Alibaba Health (0241.HK) experienced a significant stock price increase, rising nearly 6% and surpassing HKD 6, with a latest market capitalization of HKD 96.4 billion [1] Group 1: Demand Surge - Demand for antiviral drugs for influenza has notably increased, with the number of buyers rising fivefold over the past two weeks (November 10 to 23) [1] - The purchase of the antiviral drug Mabalosavir saw a more than sixfold increase, leading the growth in demand [1] - The number of buyers for antiviral oral liquids also increased by 50% [1] Group 2: Market Insights - Experts indicate that the H3N2 strain circulating this year is different from previous years, resulting in lower immunity among the population and facilitating easier transmission [1] - As a platform, Alibaba Health benefits from both self-operated businesses (such as Alibaba Health Pharmacy) and commissions and service fees from third-party merchants on the Tmall Medicine platform [1] - The fivefold increase in demand for antiviral drugs directly translates to a surge in order volume and sales, leading to increased revenue and profit for Alibaba Health [1]

Core Viewpoint - The company reported significant growth in its business operations, particularly in its proprietary brand segment, indicating strong market performance and potential for future expansion [1] Group 1: Financial Performance - The total transaction volume for the company's flagship business, including its proprietary brand operations, reached approximately 658.4 million yuan in the third quarter of 2025, representing a year-on-year increase of 163% [1] - The transaction volume for the company's proprietary brand business was approximately 491.5 million yuan, showing a remarkable year-on-year growth of 334.2% [1]